Safety Study of Stem Cells Treatment in Diabetic Foot Ulcers
NCT ID: NCT01686139
Last Updated: 2016-01-27
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE1
Total Enrollment
12 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-03-31
Study Completion Date
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Diabetes Mellitus (DM) can be regarded as one of the "epidemics" of the western world.
DM contributes to severe morbidity and mortality due to damage in the target organs (neuropathy, vasculopathy, nephropathy, retinopathy).
It affects the quality of life of the patients because of increased rate of blindness, IHD, stroke, end stage renal failure, hemodialysis and lower limb amputations (LLA).The Diabetic Foot (DF) is defined as destruction or infection of tissue/s in the foot of diabetic patients due to neurological damage and / or different levels of Peripheral Vascular Disease (PVD). Diabetic foot complications are the most common cause of lower extremity amputations in the industrialized world. The lifetime occurence of Diabetic Foot Ulcers (DFU) is 20% in diabetic patients.
Between 15% - 25% of the foot ulcers will lead to lower limb amputations.
It has been shown that Mesenchymal Stem Cells (MSCs) could be an effective therapy for many diseases including acute respiratory distress syndrome, spinal cord injury, liver injury and critical limb ischemia.
Stem cells can be obtained from either the patient (autologous) or non-related healthy donors (allogeneic).
The purpose of this study is to determine the safety and efficacy of cultured Bone Marrow Mesenchymal Stromal Cells (BM-MSCs) from allogeneic donors for treatment of chronic leg wounds of diabetic patients.
DM contributes to severe morbidity and mortality due to damage in the target organs (neuropathy, vasculopathy, nephropathy, retinopathy).
It affects the quality of life of the patients because of increased rate of blindness, IHD, stroke, end stage renal failure, hemodialysis and lower limb amputations (LLA).The Diabetic Foot (DF) is defined as destruction or infection of tissue/s in the foot of diabetic patients due to neurological damage and / or different levels of Peripheral Vascular Disease (PVD). Diabetic foot complications are the most common cause of lower extremity amputations in the industrialized world. The lifetime occurence of Diabetic Foot Ulcers (DFU) is 20% in diabetic patients.
Between 15% - 25% of the foot ulcers will lead to lower limb amputations.
It has been shown that Mesenchymal Stem Cells (MSCs) could be an effective therapy for many diseases including acute respiratory distress syndrome, spinal cord injury, liver injury and critical limb ischemia.
Stem cells can be obtained from either the patient (autologous) or non-related healthy donors (allogeneic).
The purpose of this study is to determine the safety and efficacy of cultured Bone Marrow Mesenchymal Stromal Cells (BM-MSCs) from allogeneic donors for treatment of chronic leg wounds of diabetic patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer
NCT06231771
Diabetic Foot Ulcer
NOT_YET_RECRUITING
PHASE1/PHASE2
Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells
NCT03865394
Diabetic Foot Ulcer
COMPLETED
PHASE1/PHASE2
Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot
NCT01216865
Diabetic Foot
Critical Limb Ischemia
Mesenchymal Stem Cells
+1 more
UNKNOWN
PHASE1/PHASE2
Effect of Mesenchymal Stem Cells on Healing of Foot Ulcers in Diabetes Patients.
NCT05595681
Diabetic Foot Ulcer
Mesenchymal Stromal Cells
TERMINATED
PHASE1
Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs
NCT02866565
Diabetic Foot Ulcer
NOT_YET_RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type I Diabetes Mellitus With Ulcer
Type II Diabetes Mellitus With Ulcer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ABDM-MSC
The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).
Maximal amount of ABMD-MSC cells injected: 10-20\*10\^6 cells (up to volume of 20mL, depending on the wound size \& patient weight).
Group Type
EXPERIMENTAL
ABMD-MSC
Intervention Type
BIOLOGICAL
10-20 x 10\^6 cells/20mL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABMD-MSC
10-20 x 10\^6 cells/20mL
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient signed informed consent.
* Adult males or females between 18 and 81 years of age with diabetes mellitus type 1 or type 2.
* Patient has one Diabetic Foot Ulcer (DFU) on the treated leg. The size of the DFU is no greater than 10 cm2 .
* The Diabetic Foot Ulcer (DFU) is neuropathic: The patient is checked by a 5.27 mm Monofilament, and doesn't have a sensation in at least 4 of 9 points in the foot.
* No endovascular or surgical interventions are planned.
* Patient isn't in an immediate life threat.
* Normal organ and marrow function as defined:
1. Leukocytes ≥3,000/μL
2. Absolute neutrophil count ≥1,500/μL
3. Platelets ≥140,000/μL
4. AST (SGOT)/ALT (SGPT) ≤2.5 X institutional standards range
5. Creatinine ≤ 2.5 mg/dL
* Patients with controlled blood pressure (defined as a systolic blood pressure ≤180 and/or a diastolic blood pressure of ≤110 mmHg) and established anti-hypertensive therapy as necessary prior to entry into the study.
* Adult males or females between 18 and 81 years of age with diabetes mellitus type 1 or type 2.
* Patient has one Diabetic Foot Ulcer (DFU) on the treated leg. The size of the DFU is no greater than 10 cm2 .
* The Diabetic Foot Ulcer (DFU) is neuropathic: The patient is checked by a 5.27 mm Monofilament, and doesn't have a sensation in at least 4 of 9 points in the foot.
* No endovascular or surgical interventions are planned.
* Patient isn't in an immediate life threat.
* Normal organ and marrow function as defined:
1. Leukocytes ≥3,000/μL
2. Absolute neutrophil count ≥1,500/μL
3. Platelets ≥140,000/μL
4. AST (SGOT)/ALT (SGPT) ≤2.5 X institutional standards range
5. Creatinine ≤ 2.5 mg/dL
* Patients with controlled blood pressure (defined as a systolic blood pressure ≤180 and/or a diastolic blood pressure of ≤110 mmHg) and established anti-hypertensive therapy as necessary prior to entry into the study.
Exclusion Criteria
* Patient weight is greater than 120 Kg.
* Patients with poorly controlled diabetes mellitus (HbA1c \> 10%).
* Presence of osteomyelitis (stage B grade 3 and stage D grade 3 on the UT Scale).
* More than one ulcer in the treated foot.
* Patients with a known failed ipsilateral revascularization procedure within 4 weeks prior to enrollment.
* Patients with ABI \<= 0.3
* Patients receiving treatment with hematopoietic growth factors.
* (Actively) infected ulcer.
* Infection of the involved extremity(ies) in the intended region of injection. Patient will be included (injected) if there is a safe zone of 10 cm from any soft tissue infection, manifested by fever, purulence and severe cellulitis.
* Active wet gangrenous tissue.
* Patients who require uninterrupted anticoagulation or anti-platelet therapy \[i.e. anticoagulation therapy (e.g. Coumadin) that cannot be stopped for 72 hours prior to intramuscular injections.
* Patients with a blood clotting disorder not caused by medication.
* Patients with known cancer undergoing treatment including chemotherapy, radiotherapy or immunotherapy.
* Patients with end stage renal disease requiring dialysis.
* Patients who are pregnant or lactating.
* History of regular alcohol consumption exceeding 2 drinks/day (1 drink = 5 oz \[150mL\] of wine or 12 oz \[360mL\] of beer or 1.5 oz \[45mL\] of hard liquor) within 6 months of screening and/or history of illicit drug use.
* Known allergies to protein products (horse or bovine serum, or porcine trypsin) used in the cell production process.
* Patients receiving experimental medications or participating in another clinical study within 30 days of screening.
* Immune deficient patients.
* Patients with positive blood tests for Hepatitis B or Hepatitis C or HIV or Syphilis at the time of screening.
* Patients treated by Ilomedin (Iloprost).
* Patients having received a new chronic pharmacologic treatment regimen within 4 weeks prior to enrollment.
* Patients undergoing hyperbaric oxygen treatment within 4 weeks of inclusion and/or required throughout the trial.
* Concomitant wound treatments that include growth factors or tissue engineered products.
* In the opinion of the investigator, the patient is unsuitable for cellular therapy.
* Patients receiving systemic or direct target limb injection of antiangiogenic drugs.
* Patients with poorly controlled diabetes mellitus (HbA1c \> 10%).
* Presence of osteomyelitis (stage B grade 3 and stage D grade 3 on the UT Scale).
* More than one ulcer in the treated foot.
* Patients with a known failed ipsilateral revascularization procedure within 4 weeks prior to enrollment.
* Patients with ABI \<= 0.3
* Patients receiving treatment with hematopoietic growth factors.
* (Actively) infected ulcer.
* Infection of the involved extremity(ies) in the intended region of injection. Patient will be included (injected) if there is a safe zone of 10 cm from any soft tissue infection, manifested by fever, purulence and severe cellulitis.
* Active wet gangrenous tissue.
* Patients who require uninterrupted anticoagulation or anti-platelet therapy \[i.e. anticoagulation therapy (e.g. Coumadin) that cannot be stopped for 72 hours prior to intramuscular injections.
* Patients with a blood clotting disorder not caused by medication.
* Patients with known cancer undergoing treatment including chemotherapy, radiotherapy or immunotherapy.
* Patients with end stage renal disease requiring dialysis.
* Patients who are pregnant or lactating.
* History of regular alcohol consumption exceeding 2 drinks/day (1 drink = 5 oz \[150mL\] of wine or 12 oz \[360mL\] of beer or 1.5 oz \[45mL\] of hard liquor) within 6 months of screening and/or history of illicit drug use.
* Known allergies to protein products (horse or bovine serum, or porcine trypsin) used in the cell production process.
* Patients receiving experimental medications or participating in another clinical study within 30 days of screening.
* Immune deficient patients.
* Patients with positive blood tests for Hepatitis B or Hepatitis C or HIV or Syphilis at the time of screening.
* Patients treated by Ilomedin (Iloprost).
* Patients having received a new chronic pharmacologic treatment regimen within 4 weeks prior to enrollment.
* Patients undergoing hyperbaric oxygen treatment within 4 weeks of inclusion and/or required throughout the trial.
* Concomitant wound treatments that include growth factors or tissue engineered products.
* In the opinion of the investigator, the patient is unsuitable for cellular therapy.
* Patients receiving systemic or direct target limb injection of antiangiogenic drugs.
Minimum Eligible Age
18 Years
Maximum Eligible Age
81 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sheba Medical Center
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Itzhak Siev-Ner
Head of the Orthopedic Rehabilitation Department
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Itzhak Siev-Ner, MD
Role: PRINCIPAL_INVESTIGATOR
Sheba Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orthopedic Rehabilitation out-patient clinic, Sheba Medical Center
Ramat Gan, , Israel
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Israel
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 1976 Sep;4(5):267-74.
Reference Type
BACKGROUND
Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):419-27. doi: 10.1016/j.cytogfr.2009.10.002. Epub 2009 Nov 18.
Reference Type
BACKGROUND
Wu Y, Zhao RC, Tredget EE. Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells. 2010 May;28(5):905-15. doi: 10.1002/stem.420.
Reference Type
BACKGROUND
Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R. Mesenchymal stem cells for clinical application. Vox Sang. 2010 Feb;98(2):93-107. doi: 10.1111/j.1423-0410.2009.01227.x. Epub 2009 Aug 3.
Reference Type
BACKGROUND
Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008 Apr 2;3(4):e1886. doi: 10.1371/journal.pone.0001886.
Reference Type
BACKGROUND
Fu X, Fang L, Li X, Cheng B, Sheng Z. Enhanced wound-healing quality with bone marrow mesenchymal stem cells autografting after skin injury. Wound Repair Regen. 2006 May-Jun;14(3):325-35. doi: 10.1111/j.1743-6109.2006.00128.x.
Reference Type
BACKGROUND
McFarlin K, Gao X, Liu YB, Dulchavsky DS, Kwon D, Arbab AS, Bansal M, Li Y, Chopp M, Dulchavsky SA, Gautam SC. Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. Wound Repair Regen. 2006 Jul-Aug;14(4):471-8. doi: 10.1111/j.1743-6109.2006.00153.x.
Reference Type
BACKGROUND
Wu Y, Wang J, Scott PG, Tredget EE. Bone marrow-derived stem cells in wound healing: a review. Wound Repair Regen. 2007 Sep-Oct;15 Suppl 1:S18-26. doi: 10.1111/j.1524-475X.2007.00221.x.
Reference Type
BACKGROUND
Kwon DS, Gao X, Liu YB, Dulchavsky DS, Danyluk AL, Bansal M, Chopp M, McIntosh K, Arbab AS, Dulchavsky SA, Gautam SC. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J. 2008 Jun;5(3):453-63. doi: 10.1111/j.1742-481X.2007.00408.x.
Reference Type
BACKGROUND
Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007 May;117(5):1219-22. doi: 10.1172/JCI32169.
Reference Type
BACKGROUND
Iwase T, Nagaya N, Fujii T, Itoh T, Murakami S, Matsumoto T, Kangawa K, Kitamura S. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res. 2005 Jun 1;66(3):543-51. doi: 10.1016/j.cardiores.2005.02.006. Epub 2005 Mar 2.
Reference Type
BACKGROUND
Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003 Jun;9(6):702-12. doi: 10.1038/nm0603-702.
Reference Type
BACKGROUND
Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, Shrayer D, Carson P. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng. 2007 Jun;13(6):1299-312. doi: 10.1089/ten.2006.0278.
Reference Type
BACKGROUND
Kirana S, Stratmann B, Lammers D, Negrean M, Stirban A, Minartz P, Koerperich H, Gastens MH, Gotting C, Prohaska W, Kleesiek K, Tschoepe D. Wound therapy with autologous bone marrow stem cells in diabetic patients with ischaemia-induced tissue ulcers affecting the lower limbs. Int J Clin Pract. 2007 Apr;61(4):690-2. doi: 10.1111/j.1742-1241.2007.01303.x.
Reference Type
BACKGROUND
Dash NR, Dash SN, Routray P, Mohapatra S, Mohapatra PC. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res. 2009 Oct;12(5):359-66. doi: 10.1089/rej.2009.0872.
Reference Type
BACKGROUND
Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8932-7. doi: 10.1073/pnas.132252399.
Reference Type
BACKGROUND
Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, Kogler G, Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002 Oct 8;106(15):1913-8. doi: 10.1161/01.cir.0000034046.87607.1c.
Reference Type
BACKGROUND
Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004 Jul 1;94(1):92-5. doi: 10.1016/j.amjcard.2004.03.034.
Reference Type
BACKGROUND
Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grogaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1199-209. doi: 10.1056/NEJMoa055706.
Reference Type
BACKGROUND
Fuchs S, Kornowski R, Weisz G, Satler LF, Smits PC, Okubagzi P, Baffour R, Aggarwal A, Weissman NJ, Cerqueira M, Waksman R, Serrruys P, Battler A, Moses JW, Leon MB, Epstein SE. Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol. 2006 Mar 15;97(6):823-9. doi: 10.1016/j.amjcard.2005.09.132. Epub 2006 Jan 30.
Reference Type
BACKGROUND
Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A. Spontaneous human adult stem cell transformation. Cancer Res. 2005 Apr 15;65(8):3035-9. doi: 10.1158/0008-5472.CAN-04-4194.
Reference Type
BACKGROUND
Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG, Zuffardi O, Locatelli F. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007 Oct 1;67(19):9142-9. doi: 10.1158/0008-5472.CAN-06-4690.
Reference Type
BACKGROUND
Miura Y, Gao Z, Miura M, Seo BM, Sonoyama W, Chen W, Gronthos S, Zhang L, Shi S. Mesenchymal stem cell-organized bone marrow elements: an alternative hematopoietic progenitor resource. Stem Cells. 2006 Nov;24(11):2428-36. doi: 10.1634/stemcells.2006-0089.
Reference Type
BACKGROUND
Dahl JA, Duggal S, Coulston N, Millar D, Melki J, Shahdadfar A, Brinchmann JE, Collas P. Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Int J Dev Biol. 2008;52(8):1033-42. doi: 10.1387/ijdb.082663jd.
Reference Type
BACKGROUND
Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, Tchirkov A, Rouard H, Henry C, Splingard M, Dulong J, Monnier D, Gourmelon P, Gorin NC, Sensebe L; Societe Francaise de Greffe de Moelle et Therapie Cellulaire. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood. 2010 Feb 25;115(8):1549-53. doi: 10.1182/blood-2009-05-219907. Epub 2009 Dec 23.
Reference Type
BACKGROUND
Rosland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, Mysliwietz J, Tonn JC, Goldbrunner R, Lonning PE, Bjerkvig R, Schichor C. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009 Jul 1;69(13):5331-9. doi: 10.1158/0008-5472.CAN-08-4630. Epub 2009 Jun 9.
Reference Type
BACKGROUND
Garcia S, Bernad A, Martin MC, Cigudosa JC, Garcia-Castro J, de la Fuente R. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res. 2010 May 15;316(9):1648-50. doi: 10.1016/j.yexcr.2010.02.016. Epub 2010 Feb 18. No abstract available.
Reference Type
BACKGROUND
Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, Simmons PJ, Sensebe L, Keating A. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010 Sep;12(5):576-8. doi: 10.3109/14653249.2010.507330.
Reference Type
BACKGROUND
Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF, Schultz GS. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen. 2002 Jan-Feb;10(1):26-37. doi: 10.1046/j.1524-475x.2002.10903.x.
Reference Type
BACKGROUND
Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen. 1996 Oct;4(4):411-20. doi: 10.1046/j.1524-475X.1996.40404.x.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHEBA-11-8802-IS-SMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Adipose Derived Regenerative Cells In the Treatment of Diabetic Foot Ulcers
NCT05095389
UNKNOWN
PHASE3
Mesenchymal Stromal Cell Derivatives in the Treatment of Chronic Diabetic Foot Ulcers Type 1 and 2
NCT02943486
UNKNOWN
PHASE1/PHASE2
Study for Treatment of Chronic Diabetic Foot Ulcers With the Investigational Allogeneic Cell Therapy Product, hOMSC200
NCT06003530
ACTIVE_NOT_RECRUITING
PHASE1
Human Placental Mesenchymal Stem Cells Treatment on Diabetic Foot Ulcer
NCT04464213
UNKNOWN
PHASE1
Topical Erythropoietin Hydrogel Formulation for Diabetic Foot Ulcers
NCT02361931
COMPLETED
PHASE1/PHASE2
Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers
NCT00330265
UNKNOWN
PHASE2
Cell Therapy for Diabetic Foot Ulcer
NCT05234086
UNKNOWN
PHASE2
Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot (FOOTCELL)
NCT06843122
NOT_YET_RECRUITING
PHASE2
Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
NCT02092870
COMPLETED
PHASE2
Macrophage Stimulating Factor in the Treatment of Diabetic Wounds
NCT06608303
COMPLETED
NA
Clinical Application of Mesenchymal Stem Cells Seeded in Chitosan Scaffold for Diabetic Foot Ulcers
NCT03259217
UNKNOWN
PHASE1
Local Application of Autologous Bone Marrow Cells for Treatment of Chronic Diabetic Ulcers
NCT00292357
UNKNOWN
PHASE1
Stem Cell Study for Patients With Leg Ulcer/Gangrene
NCT00221143
COMPLETED
PHASE1/PHASE2
Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers
NCT00387101
TERMINATED
PHASE3
Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers
NCT01353937
WITHDRAWN
PHASE1
Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: A Double-blinded Randomized Controlled Clinical Trial
NCT06812637
COMPLETED
PHASE1
A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers
NCT06852976
RECRUITING
PHASE2
Utilization of Platelet Gel for Treatment of Diabetic Foot Ulcers
NCT02134132
COMPLETED
PHASE1/PHASE2
Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers
NCT05610865
RECRUITING
PHASE1
A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers
NCT01070433
COMPLETED
PHASE2
A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers
NCT00351767
COMPLETED
PHASE2
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
NCT01830348
TERMINATED
PHASE3
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
NCT05608187
TERMINATED
PHASE2
TWB-103 for Treating Lower Limb Ulcers on Patients With DM
NCT03624023
COMPLETED
PHASE1/PHASE2
Clinical Study of Adipose-derived Stem Cells in the Treatment of Diabetic Foot
NCT03916211
UNKNOWN
EARLY_PHASE1